LivaNova PLC (LIVN)
Market Cap | 2.52B |
Revenue (ttm) | 1.05B |
Net Income (ttm) | -81.87M |
Shares Out | 53.77M |
EPS (ttm) | -1.54 |
PE Ratio | n/a |
Forward PE | 24.45 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 297,689 |
Open | 46.08 |
Previous Close | 45.60 |
Day's Range | 45.84 - 46.92 |
52-Week Range | 40.26 - 70.57 |
Beta | 0.86 |
Analysts | Buy |
Price Target | 56.25 (+20.06%) |
Earnings Date | May 3, 2023 |
About LIVN
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device tha... [Read more]
Financial Performance
In 2022, LivaNova's revenue was $1.02 billion, a decrease of -1.31% compared to the previous year's $1.04 billion. Losses were -$86.25 million, -36.50% less than in 2021.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for LIVN stock is "Buy." The 12-month stock price forecast is $56.25, which is an increase of 20.06% from the latest price.
News

Primecap Management Pumps Up LivaNova Position
Media-shy investment firm PRIMECAP Management (Trades, Portfolio) revealed earlier this week it upped its stake in LivaNova PLC ( LIVN , Financial), which had an impact of 0.04% on the equity portfoli...

LivaNova Reports First-Quarter 2023 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today reported results for the quarter ended March 31, 2023 and raised full-year 2023 guidance.

LivaNova Board of Directors Announce Leadership Changes
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced that Damien McDonald has resigned as Chief Executive Officer. Effectiv...

LivaNova to Announce First-Quarter 2023 Results
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, Ma...

LivaNova Receives U.S. FDA 510(k) Clearance for Essenz Heart-Lung Machine for Cardiopulmonary Bypass Procedures
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance f...

LivaNova to Present at the Barclays Global Healthcare Conference
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present in a fireside c...

LivaNova Reports Fourth-Quarter and Full-Year 2022 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023.

LivaNova Initiates Limited Commercial Release in Europe of the Essenz Perfusion System for Cardiopulmonary Bypass Procedures
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC today announced the start of a limited commercial release in Europe for the Essenz™ Perfusion System.

LivaNova Launches SenTiva DUO
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today launched SenTiva DUO™, an implantable pulse generator (IPG) with a dual-pin he...

LivaNova to Announce Fourth-Quarter and Full-Year 2022 Results
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2022 results...

LivaNova Announces Receipt of Close-Out of Warning Letter from U.S. Food and Drug Administration
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received a close-out letter from the U.S. Food and Drug Administr...

LivaNova to Present Scientific Data at American Epilepsy Society 2022 Annual Meeting
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) 2022 Annual...

LivaNova Receives 510(k) Clearance for ECMO from FDA for LifeSPARC, the Next-generation Advanced Circulatory Support System
LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received 510(k) clearance for extracorporeal membrane oxygenation...

LivaNova to Present at the Stifel, Wolfe and Piper Sandler Healthcare Conferences
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC announced its CEO Damien McDonald will present in fireside chats at three healthcare conferences in New York this month.

LivaNova Reports Third-Quarter 2022 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 3...

LivaNova to Announce Third-Quarter 2022 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC will host a conference call to discuss its third-quarter 2022 results on Wednesday, Nov. 2, 2022, at 12 p.m. London time (8 a.m. EDT...

LivaNova Board Appoints Brooke Story as a New Director
LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC today announced the LivaNova Board of Directors appointed Brooke Story to the Board, effective September 15, 2022.

LivaNova Reports Second-Quarter 2022 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC, a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2022.

LivaNova to Announce Second-Quarter 2022 Results
LONDON--(BUSINESS WIRE)--LivaNova PLC will host a conference call to discuss its second-quarter 2022 results on Wednesday, August 3, 2022 at 1 p.m. London time (8 a.m. EDT).

LivaNova Elects Peter Wilver to Board of Directors
LONDON--(BUSINESS WIRE)--LivaNova PLC today announced Peter Wilver has been elected to the Board of Directors, effective immediately.

LivaNova to Present at the Goldman Sachs Global Healthcare Conference
LONDON--(BUSINESS WIRE)--LivaNova PLC announced CEO Damien McDonald will present in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15.

LivaNova Reports First-Quarter 2022 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC, a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2022.

LivaNova Initiates Targeted Commercial Launch of the Essenz Patient Monitor for Cardiopulmonary Bypass Procedures
LONDON--(BUSINESS WIRE)--LivaNova PLC today announced receipt of regulatory approvals and the start of a targeted commercial launch for the Essenz Patient Monitor.

LivaNova to Announce First-Quarter 2022 Results
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC will host a conference call to discuss its first-quarter 2022 results on Wednesday, May 4, 2022 at 1 p.m. London time (8 a.m. EDT).

LivaNova Announces 250th Unipolar Depression Patient Implanted in RECOVER Clinical Study
LONDON--(BUSINESS WIRE)-- #depression--LivaNova PLC today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study.